WO2010056048A2 - 아릴옥시아세틸계 화합물을 유효성분으로 포함하는 dna 메틸트랜스퍼레이즈 억제용 약학적 조성물 - Google Patents
아릴옥시아세틸계 화합물을 유효성분으로 포함하는 dna 메틸트랜스퍼레이즈 억제용 약학적 조성물 Download PDFInfo
- Publication number
- WO2010056048A2 WO2010056048A2 PCT/KR2009/006643 KR2009006643W WO2010056048A2 WO 2010056048 A2 WO2010056048 A2 WO 2010056048A2 KR 2009006643 W KR2009006643 W KR 2009006643W WO 2010056048 A2 WO2010056048 A2 WO 2010056048A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aryloxyacetyl
- dna
- based compounds
- present
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
- C07C235/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
본 발명은 화학식 1로 표시되는 아릴옥시아세틸계 화합물을 유효성분으로 함유하는 DNA 메틸렌트랜스퍼레이즈 억제용 약학적 조성물에 관한 것으로, 본 발명에 의한 조성물은 DNA 과메틸화(DNA hypermethylation)에 의해 유발되는 질환 인항종양, 뇌신경 질환, 혈액질환, 후생유전 질환의 치료제로 사용될 수 있다. 또한, 본 발명은 DNA 메틸트랜스퍼레이즈 억제제 또는 DNA 메틸레이션 억제제를 제조하기 위해 하기 화학식(1)로 표시되는 아릴옥시아세틸계 화합물 또는 이의 약학적으로 허용가능한 염을 사용하는 용도 제공한다. 본 발명은 화학식 1로 표시되는 아릴옥시아세틸계 화합물 (LW6) 또는 이의 약학적으로 허용되는 염을 DNA 메틸트랜스퍼레이즈 억제 또는 DNA 메틸레이션 억제를 필요로 하는 포유류(인간 포함)에게 투여함으로서 DNA 과메틸화에 의해 유발되는 질환을 치료하는 방법을 제공한다.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2008-0112141 | 2008-11-12 | ||
KR1020080112141A KR20100053150A (ko) | 2008-11-12 | 2008-11-12 | 아릴옥시아세틸계 유도체를 유효성분으로 포함하는 dna 메틸트렌스퍼레이즈 억제용 약학적 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010056048A2 true WO2010056048A2 (ko) | 2010-05-20 |
WO2010056048A3 WO2010056048A3 (ko) | 2010-08-26 |
Family
ID=42170522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2009/006643 WO2010056048A2 (ko) | 2008-11-12 | 2009-11-12 | 아릴옥시아세틸계 화합물을 유효성분으로 포함하는 dna 메틸트랜스퍼레이즈 억제용 약학적 조성물 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20100053150A (ko) |
WO (1) | WO2010056048A2 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2760823A4 (en) * | 2011-09-27 | 2015-05-20 | Univ Dongguk Ind Acad Coop | NEW COMPOUNDS AS A HIF-1 INHIBITOR AND METHOD OF MANUFACTURING THEREOF |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020060991A (ko) * | 1999-12-09 | 2002-07-19 | 아스트라제네카 아베 | 아다만탄 유도체 |
KR20050101559A (ko) * | 2003-02-21 | 2005-10-24 | 아스트라제네카 아베 | 아다만탄 유도체, 이의 제조 방법 및 이를 함유하는 제약조성물 |
KR100787131B1 (ko) * | 2006-07-04 | 2007-12-21 | 한국생명공학연구원 | Hif―1 활성을 저해하는 화합물, 이의 제조방법 및이를 유효성분으로 함유하는 약학적 조성물 |
-
2008
- 2008-11-12 KR KR1020080112141A patent/KR20100053150A/ko not_active Application Discontinuation
-
2009
- 2009-11-12 WO PCT/KR2009/006643 patent/WO2010056048A2/ko active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020060991A (ko) * | 1999-12-09 | 2002-07-19 | 아스트라제네카 아베 | 아다만탄 유도체 |
KR20050101559A (ko) * | 2003-02-21 | 2005-10-24 | 아스트라제네카 아베 | 아다만탄 유도체, 이의 제조 방법 및 이를 함유하는 제약조성물 |
KR100787131B1 (ko) * | 2006-07-04 | 2007-12-21 | 한국생명공학연구원 | Hif―1 활성을 저해하는 화합물, 이의 제조방법 및이를 유효성분으로 함유하는 약학적 조성물 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2760823A4 (en) * | 2011-09-27 | 2015-05-20 | Univ Dongguk Ind Acad Coop | NEW COMPOUNDS AS A HIF-1 INHIBITOR AND METHOD OF MANUFACTURING THEREOF |
AU2012316941B2 (en) * | 2011-09-27 | 2016-02-25 | Dongguk University Industry-Academic Cooperation Foundation | Novel compounds as HIF-1alphainhibitors and manufacturing process thereof |
US9315507B2 (en) | 2011-09-27 | 2016-04-19 | Dongguk University Industry-Academic Cooperation Foundation | Compounds as HIF-1alphainhibitors and manufacturing process thereof |
Also Published As
Publication number | Publication date |
---|---|
KR20100053150A (ko) | 2010-05-20 |
WO2010056048A3 (ko) | 2010-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010022055A3 (en) | 1, 3, 5 -triaz ine derivatives useful in the treatment of chronic pain disorders | |
EP2650293A8 (en) | [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof | |
WO2006067445A3 (en) | Csf-1r kinase inhibitors | |
MXPA04012965A (es) | Inhibidores virales. | |
SI1761528T1 (sl) | 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2H-pirido(2,3-D)pirimidinski derivati in sorodne spojine za zdravljenje raka | |
UA86614C2 (ru) | Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата | |
EA201000552A1 (ru) | Производные пирроло[2,3-d]пиримидина в качестве ингибиторов протеинкиназы в | |
WO2008005956A3 (en) | Pyrrolotriazine kinase inhibitors | |
WO2009155121A3 (en) | Inhibitors of pi3 kinase | |
DE602004007239D1 (de) | 4-AMINOTHIENOÄ2,3-dÜ PYRIMIDIN -6-CARBONITRIL-DERIVATIVE ZUR VERWENDUNG ALS PDE7 INHIBITOREN | |
PL2324008T3 (pl) | 3,4-diarylopirazole jako inhibitory kinazy białkowej | |
WO2007070598A8 (en) | Nucleotide and oligonucleotide prodrugs | |
WO2008054454A3 (en) | Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents | |
MX2019011954A (es) | Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b ][1,2,4]triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas. | |
WO2009030952A3 (en) | Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway | |
MX2010006748A (es) | Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2. | |
GEP20125459B (en) | Compounds for inhibiting mitotic progression | |
WO2008023258A8 (en) | Piperidine derivatives | |
TW200745136A (en) | 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid derivatives | |
WO2006116733A3 (en) | Protein kinase inhibitors | |
WO2007092936A3 (en) | Method to treat gastric lesions | |
GB0112348D0 (en) | Compounds | |
MY150075A (en) | Novel phosphodiesterase inhibitors | |
UA104988C2 (uk) | Похідні піроніндолу та спосіб їх отримання | |
WO2012064897A3 (en) | Bicyclic and tricyclic inhibitors of sumoylation enzymes and methods for their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09826280 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09826280 Country of ref document: EP Kind code of ref document: A2 |